

10/085.239

Inventor Search Notes  
2/4/05

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptalat1614

PASSWORD:

LOGINID/PASSWORD REJECTED

The loginid and/or password sent to STN were invalid.  
You either typed them incorrectly, or line noise may  
have corrupted them.

Do you wish to retry the logon?

Enter choice (y/N):

Do you wish to use the same loginid and password?

Enter choice (y/N):

Enter new loginid (or press [Enter] for sssptalat1614):

Enter new password:

LOGINID:

LOGINID:275h897

PASSWORD:

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptalat1614

PASSWORD:

LOGINID/PASSWORD REJECTED

The loginid and/or password sent to STN were invalid.  
You either typed them incorrectly, or line noise may  
have corrupted them.

Do you wish to retry the logon?

Enter choice (y/N):

Do you wish to use the same loginid and password?

Enter choice (y/N):

Enter new loginid (or press [Enter] for sssptalat1614):

Enter new password:

LOGINID:

LOGINID:sssptalar1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3	SEP 01 New pricing for the Save Answers for SciFinder Wizard within

STN Express with Discover!

NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	JAN 26	CA/CAPLUS - Expanded patent coverage to include the Russian Agency for Patents and Trademarks (ROSPATENT)

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:41:57 ON 04 FEB 2005

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 09:42:03 ON 04 FEB 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 4 Feb 2005 VOL 142 ISS 6  
FILE LAST UPDATED: 2 Feb 2005 (20050202/ED)

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> e ward, s?/au

E1	15	WARD YVONA/AU
E2	1	WARD ZOE/AU
E3	0 -->	WARD, S?/AU
E4	3	WARDA A/AU
E5	1	WARDA ANGELIKA/AU
E6	1	WARDA BOGDAN/AU
E7	4	WARDA BOGDAN JACEK/AU
E8	4	WARDA CZESLAW/AU
E9	10	WARDA E/AU
E10	1	WARDA EDWARD B II/AU
E11	4	WARDA EUGENIUSZ/AU
E12	2	WARDA H A/AU

=> e ward s?/au

E1	2	WARD S S/AU
E2	1	WARD S T/AU
E3	0 -->	WARD S?/AU
E4	6	WARD SALLY/AU
E5	3	WARD SALLY A/AU
E6	3	WARD SALLY P/AU
E7	2	WARD SAMANTHA/AU
E8	1	WARD SAMANTHA M/AU
E9	43	WARD SAMUEL/AU
E10	2	WARD SAMUEL A/AU
E11	2	WARD SAMUEL ABNER/AU
E12	2	WARD SAMUEL C/AU

=> e ward simon/au

E1	1	WARD SHERRY LYNN/AU
E2	1	WARD SHIRLEY P/AU
E3	30 -->	WARD SIMON/AU
E4	8	WARD SIMON E/AU
E5	5	WARD SIMON EDWARD/AU
E6	19	WARD SIMON J/AU
E7	2	WARD SIMON JAMES/AU
E8	1	WARD SIMON M/AU
E9	1	WARD SIMONE A/AU
E10	8	WARD SIMONE M/AU
E11	6	WARD SIMONE VISOSKY/AU
E12	1	WARD SLINGERLAND D/AU

=> s e3-e5

	30	"WARD SIMON"/AU
	8	"WARD SIMON E"/AU
	5	"WARD SIMON EDWARD"/AU
L1	43	("WARD SIMON"/AU OR "WARD SIMON E"/AU OR "WARD SIMON EDWARD"/AU)

=> e bavik claes/au

E1	24	BAVIERE MARC/AU
E2	1	BAVIERE R/AU
E3	11 -->	BAVIK CLAES/AU
E4	4	BAVIK CLAES O/AU
E5	3	BAVIK CLAES OLOF/AU
E6	1	BAVIK K/AU

E7	1	BAVIKA ANDREJ V/AU
E8	45	BAVIKA L I/AU
E9	1	BAVIKA LEONID I/AU
E10	4	BAVIKA N P/AU
E11	4	BAVIKA V A/AU
E12	80	BAVIKA V I/AU

=> s e3-e5

	11	"BAVIK CLAES"/AU
	4	"BAVIK CLAES O"/AU
	3	"BAVIK CLAES OLOF"/AU
L2	18	("BAVIK CLAES"/AU OR "BAVIK CLAES O"/AU OR "BAVIK CLAES OLOF"/AU )

=> e cork michael/au

E1	1	CORK M JOSEPH/AU
E2	11	CORK MARGARET S/AU
E3	10 -->	CORK MICHAEL/AU
E4	14	CORK MICHAEL J/AU
E5	3	CORK MICHAEL S/AU
E6	1	CORK MIKE/AU
E7	1	CORK PHILIP/AU
E8	1	CORK R/AU
E9	3	CORK R C/AU
E10	1	CORK R H/AU
E11	9	CORK R J/AU
E12	12	CORK R JOHN/AU

=> s e3-e4

	10	"CORK MICHAEL"/AU
	14	"CORK MICHAEL J"/AU
L3	24	("CORK MICHAEL"/AU OR "CORK MICHAEL J"/AU)

=> e tazi-aahnini rachid/au

E1	6	TAZI T/AU
E2	1	TAZI TOURIA/AU
E3	0 -->	TAZI-AAHNINI RACHID/AU
E4	1	TAZIAUX D/AU
E5	1	TAZIAUX MELANIE/AU
E6	1	TAZIAUX P/AU
E7	1	TAZIBT A/AU
E8	1	TAZIDDINOV G/AU
E9	3	TAZIEFF DEPIERRE F/AU
E10	43	TAZIEFF DEPIERRE FRANCE/AU
E11	1	TAZIEFF DEPIERRE MRS FRANCE/AU
E12	16	TAZIEFF H/AU

=> e taziaahnini rachid/au

E1	6	TAZI T/AU
E2	1	TAZI TOURIA/AU
E3	0 -->	TAZIAAHNINI RACHID/AU
E4	1	TAZIAUX D/AU
E5	1	TAZIAUX MELANIE/AU
E6	1	TAZIAUX P/AU
E7	1	TAZIBT A/AU
E8	1	TAZIDDINOV G/AU
E9	3	TAZIEFF DEPIERRE F/AU
E10	43	TAZIEFF DEPIERRE FRANCE/AU
E11	1	TAZIEFF DEPIERRE MRS FRANCE/AU
E12	16	TAZIEFF H/AU

=> s l1 or l2 or l3

L4	71	L1 OR L2 OR L3
----	----	----------------

=> file stnguide  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
18.27	18.48

FILE 'STNGUIDE' ENTERED AT 09:46:14 ON 04 FEB 2005  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Jan 28, 2005 (20050128/UP).

=> file caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.24	18.72

FILE 'CAPLUS' ENTERED AT 09:48:23 ON 04 FEB 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Feb 2005 VOL 142 ISS 6  
FILE LAST UPDATED: 2 Feb 2005 (20050202/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 09:41:57 ON 04 FEB 2005)

FILE 'CAPLUS' ENTERED AT 09:42:03 ON 04 FEB 2005

	E WARD, S?/AU
	E WARD S?/AU
	E WARD SIMON/AU
L1	43 S E3-E5
	E BAVIK CLAES/AU
L2	18 S E3-E5
	E CORK MICHAEL/AU
L3	24 S E3-E4
	E TAZI-AAHNINI RACHID/AU
	E TAZIAAHNINI RACHID/AU
L4	71 S L1 OR L2 OR L3

FILE 'STNGUIDE' ENTERED AT 09:46:14 ON 04 FEB 2005

FILE 'CAPLUS' ENTERED AT 09:48:23 ON 04 FEB 2005

=> d 14 1-71 ibib abs  
THE ESTIMATED COST FOR THIS REQUEST IS 188.15 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:n  
REQUEST CANCELED

=> s 14 and (carbenoxolone? or carbeneoxolone? or carbenoxalone?)

595 CARBENOXOLONE?  
0 CARBENEOXOLONE?  
13 CARBENOXALONE?

L5 1 L4 AND (CARBENOXOLONE? OR CARBENEOXOLONE? OR CARBENOXALONE?)

=> e psoriasis

E1 72 PSORIASIN/BI  
E2 8 PSORIASINS/BI  
E3 11209 --> PSORIASIS/BI  
E4 1 PSORIASISLIKE/BI  
E5 1 PSORIASISOR/BI  
E6 1 PSORIAS/BI  
E7 1 PSORIASTATIN/BI  
E8 1 PSORIASTIC/BI  
E9 1 PSORIASTICS/BI  
E10 2659 PSORIATIC/BI  
E11 4 PSORIATICALLY/BI  
E12 131 PSORIATICS/BI

=> s e3

L6 11209 PSORIASIS/BI

=> s 14 and 16

L7 11 L4 AND L6

=> d 17 1-11 ibib abs

L7 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:775091 CAPLUS

DOCUMENT NUMBER: 141:392710

TITLE: Genome-wide studies of **psoriasis**  
susceptibility loci: a review

AUTHOR(S): Sagoo, Gurdeep S.; Cork, Michael J.; Patel,  
Ramila; Tazi-Ahnini, Rachid

CORPORATE SOURCE: D Floor Medical School, Division of Genomic Medicine,  
Biomedical Genetics Project, University of Sheffield,  
Royal Hallamshire Hospital, Sheffield, S10 2RX, UK

SOURCE: Journal of Dermatological Science (2004), 35(3),  
171-179

CODEN: JDSCEI; ISSN: 0923-1811

PUBLISHER: Elsevier Ireland Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. **Psoriasis** is a chronic inflammatory dermatosis affecting approx. 0.3-5% world-wide. Since 1997, nine genome-wide scans have been published in the search for predisposing genes to **psoriasis** and psoriatic arthritis. These genome-wide scans have provided results that both confirm earlier work, but which also suggest novel regions of interest on the genome. This article reviews the results of these genome-wide scans, in particular two novel regions on chromosomes 3p and 15p, and compares the study types and designs. The results in these two regions were compared in the different studies providing no further suggestive evidence, and the authors suggest that these results may be false-positives, population-specific susceptibility loci or due to the stratification used in the study design. The authors suggest stratifying the data into epidemiol. subgroups to make the genome-wide scans more sensitive to loci specific to these subgroups. This approach could provide a much more powerful technique to study the genetics of a complex disease such as **psoriasis**.

REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:453389 CAPLUS  
 DOCUMENT NUMBER: 141:22226  
 TITLE: **Psoriasis** diagnostics and therapeutics  
 INVENTOR(S): **Cork, Michael J.**; Ward, Simon J.;  
 Tazi-Ahnini, Rachid  
 PATENT ASSIGNEE(S): Molecular Skincare Limited, UK  
 SOURCE: PCT Int. Appl., 55 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046380	A1	20040603	WO 2003-GB5011	20031119
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: GB 2002-27026 A 20021120

AB This invention relates to polymorphisms in the human epidermal gene cluster in the major histocompatibility complex. In particular, the invention relates to four polymorphisms in the sequence of the  $\alpha$ -helix coiled-coil rod homolog (HCR) gene, the structure of the corresponding allelic polypeptides encoded thereby, and the similarity of these polypeptides with streptococcal surface antigen M proteins. The invention provides diagnostic assays for, and methods of manufacture of medicaments for both prophylaxis and treatment of guttate **psoriasis** and/or **psoriasis vulgaris**.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:454130 CAPLUS  
 DOCUMENT NUMBER: 139:30850  
 TITLE: Disease treatment using two related compounds wherein at least one of the compound induces a tachyphylactic response which does not affect the other compound  
 INVENTOR(S): Tazi-Ahnini, Rachid; **Ward, Simon; Cork, Michael**; Duff, Gorden  
 PATENT ASSIGNEE(S): Molecular Skincare Limited, UK  
 SOURCE: PCT Int. Appl., 104 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003047594	A1	20030612	WO 2002-GB5385	20021129
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,			

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2001-28628 A 20011129

AB We disclose a method of improving a therapeutic regime, the method comprising administering to an individual in need of same: (a) a first therapeutic compound, in which the first therapeutic compound is capable of inducing a tachyphylactic response, and (b) a second therapeutic compound, in which the second therapeutic compound is not substantially affected by the tachyphylactic response, and in which the first and second therapeutic compds. are capable of modulating, preferably inducing, gene expression from a common response element. Thus, the inventors have discovered that, where patients develop tolerance (tachyphylaxis) to one drug, for example, a topical vitamin D analog such as Dovonex, when they switch to another drug (e.g., another vitamin D analog such as Curatoderm), efficacy is restored. The regime includes the sequential or rotational administration of the two related drugs. The second therapeutic compound may be a mimetic of the first therapeutic compound. Preferably, the first therapeutic compound is structurally related to the second therapeutic compound. The first therapeutic compound preferably competes with the second therapeutic compound for binding to a mol. A deactivating mol. may be used to deactivate the first or second therapeutic compound to lead to a tachyphylactic response. The deactivating mol. may comprise a metabolic enzyme. An antagonist of a deactivating mol. may also be administered. Preferably, the therapeutic regime is applied for the treatment of an epidermal disease.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:434360 CAPLUS

DOCUMENT NUMBER: 139:22211

TITLE: Aminoalkylimidazole derivatives for use as CYP24 inhibitors

INVENTOR(S): Tazi-Ahnini, Rachid; Ward, Simon; Cork, Michael; Duff, Gordon; Harritty, Joe; Bavik, Claes

PATENT ASSIGNEE(S): Molecular Skincare Limited, UK

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045381	A1	20030605	WO 2002-GB5329	20021127
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2001-28415 A 20011127

OTHER SOURCE(S): MARPAT 139:22211

GI





AB Aminoalkylimidazoles I [R1 (un)substituted Ph, quinoline, isoquinoline, anthracene; R2 =H, (un)substituted Ph; R3 = halogen, hydrocarbyl, (un)substituted Ph, N-acylpiperazinyl; X = CO, SO<sub>2</sub>; when X = CO and R1, R3 = (un)substituted Ph, R2 ≠ H; when X = CO and R2, R3 = (un)substituted Ph, R1 ≠ H] were prepared for use as CYP24 inhibitors (no data). Thus, 2-phenylaziridine was treated with 4-ClC<sub>6</sub>H<sub>4</sub>COCl, followed by imidazole to give I [X = CO, R1 = Ph, R2 = H, R3 = 4-ClC<sub>6</sub>H<sub>4</sub>].

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:449495 CAPLUS

DOCUMENT NUMBER: 137:28324

TITLE: Disease treatment by preventing tachyphylaxis to drugs by administering an antagonist of the metabolic enzyme which is induced by drug exposure

INVENTOR(S): Adcocks, Clair; **Bavik, Claes; Cork, Michael**; Duff, Gordon; Tazi-Ahnini, Rachid; **Ward, Simon**

PATENT ASSIGNEE(S): Molecular Skincare Limited, UK

SOURCE: PCT Int. Appl., 136 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002045704	A2	20020613	WO 2001-GB5369	20011204
WO 2002045704	A3	20030501		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002022125	A5	20020618	AU 2002-22125	20011204
---------------	----	----------	---------------	----------

PRIORITY APPLN. INFO.: GB 2000-29524 A 20001204

WO 2001-GB5369 W 20011204

AB The authors describe a method of alleviating or preventing a tachyphylactic response to an agent in a individual, the method comprising administering to the individual an antagonist of a metabolic enzyme which is induced as a result of exposure of the individual to the agent, in which the enzyme activity is capable of metabolizing the agent.

L7 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:429205 CAPLUS

DOCUMENT NUMBER: 137:15809  
 TITLE: Adhesion protein, protease, and protease inhibitor mutations and methods for diagnosis and treatment of epithelial cell adhesion-associated diseases  
 INVENTOR(S): Tazi-Ahnini, Rachid; **Bavik, Claes; Ward, Simon**; Duff, Gordon; **Cork, Michael**  
 PATENT ASSIGNEE(S): Molecular Skincare Limited, UK  
 SOURCE: PCT Int. Appl., 257 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002044736	A2	20020606	WO 2001-GB5303	20011130
WO 2002044736	A3	20030828		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2430473	AA	20020606	CA 2001-2430473	20011130
AU 2002020855	A5	20020611	AU 2002-20855	20011130
EP 1356298	A2	20031029	EP 2001-998835	20011130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004524010	T2	20040812	JP 2002-546227	20011130
US 2004106120	A1	20040603	US 2003-433234	20031105
PRIORITY APPLN. INFO.:				
			GB 2000-29225	A 20001130
			GB 2000-29879	A 20001207
			WO 2001-GB5303	W 20011130

AB We disclose a method of diagnosis of a disease, or susceptibility to a disease associated with abnormal cell-cell adhesion between epithelial cells, the method comprising detection of a mutation in a nucleic acid encoding an adhesion protein, a protease, or a protease inhibitor of an individual. Thus, the underlying cause of various skin diseases was shown to be the breakdown in regulation of proteolysis of adhesion proteins leading to an increased, decreased, or otherwise abnormal adhesion between corneocytes. The abnormal proteolysis was associated with mutations in adhesion protein genes (e.g., corneodesmosin gene), protease genes (e.g., stratum corneum chymotryptic enzyme or stratum corneum tryptic enzyme genes), and/or protease inhibitor genes (e.g., SKALP or SLPI genes). Treatment and prevention of such diseases was achieved by modulating the proteolysis of adhesion proteins. Transgenic mice overexpressing corneodesmosin, SCCE, or SLPI were prepared. These transgenic animals may be used as disease models.

L7 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2002:157589 CAPLUS  
 DOCUMENT NUMBER: 136:210549  
 TITLE: Retinol binding protein receptor-related treatment of hyperproliferative diseases  
 INVENTOR(S): **Ward, Simon; Bavik, Claes; Cork, Michael**; Tazi-Ahnini, Rachid  
 PATENT ASSIGNEE(S): University of Sheffield, UK  
 SOURCE: PCT Int. Appl., 139 pp.

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002015920	A2	20020228	WO 2001-GB3694	20010817
WO 2002015920	A3	20021017		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2419840	AA	20020228	CA 2001-2419840	20010817
AU 2001078632	A5	20020304	AU 2001-78632	20010817
EP 1318836	A2	20030618	EP 2001-956713	20010817
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004506691	T2	20040304	JP 2002-520841	20010817
US 2003119715	A1	20030626	US 2002-85239	20020227
PRIORITY APPLN. INFO.: GB 2000-20351 A 20000817				
WO 2001-GB3694 W 20010817				

AB Methods and compns. are provided for treating a patient suffering from a hyperproliferative disorder or photoageing. The methods involve blocking the activity of a retinol binding protein receptor (RBPr) in cells of the patient, and/or administering to the patient an antagonist of a retinol binding protein receptor (RBPr) and/or lowering the endogenous level of retinoic acid (RA) in cells of said patient.

L7 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:107080 CAPLUS  
 DOCUMENT NUMBER: 136:156443  
 TITLE: Adhesive dressings for the treatment and prophylaxis of scars  
 INVENTOR(S): **Cork, Michael**  
 PATENT ASSIGNEE(S): Strakan Pharmaceuticals Limited, UK  
 SOURCE: PCT Int. Appl., 47 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002009676	A1	20020207	WO 2001-GB3401	20010727
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2000-18466 A 20000727

AB Adhesive dressings for the treatment or prophylaxis of scars and incipient scars comprise a backing and an adhesive layer, a substance effective in

the prophylaxis and/or treatment of scarring being borne in the adhesive, the adhesive consisting essentially of a block copolymer having soft and hard segments and wherein there is chemical crosslinking between the soft segments, the adhesive further comprising at least 10 by weight of a plasticizer, such dressings having good adhesion, cohesion and high drug loading and being removable without pain or danger to sutures. A patch contained adhesive 1000, iso-Pr myristate 600 mg, 0.4% triamcinolone acetonide in ethanol 1.6, and 0.5% adipic acid dihydrazide as crosslinker 0.8 mL. The in vitro human skin penetration of triamcinolone acetonide was studied.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:185486 CAPLUS

DOCUMENT NUMBER: 133:247861

TITLE: Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to **psoriasis**. [Erratum to document cited in CA131:166023]

AUTHOR(S): Ahnini, Rachid Tazi; Camp, Nicola J.; **Cork, Michael J.**; Mee, John B.; Keohane, Stephen G.; Duff, Gordon W.; Di Giovine, Francesco S.

CORPORATE SOURCE: Division Molecular and Genetic Med., Univ. Sheffield, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK

SOURCE: Human Molecular Genetics (2000), 9(4), 659

CODEN: HMGE5; ISSN: 0964-6906

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB It was reported that HphI produced 123 + 89 bp for allele 1, while it did not cut allele 2 (212 bp). This should read: "HphI produced 123 + 89 bp for allele 2, while it did not cut allele 1 (212 bp).".

L7 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:361708 CAPLUS

DOCUMENT NUMBER: 131:166023

TITLE: Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to **psoriasis**

AUTHOR(S): Ahnini, Rachid Tazi; Camp, Nicola J.; **Cork, Michael J.**; Mee, John B.; Keohane, Stephen G.; Duff, Gordon W.; Di Giovine, Francesco S.

CORPORATE SOURCE: Division Molecular and Genetic Med., Univ. Sheffield, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK

SOURCE: Human Molecular Genetics (1999), 8(6), 1135-1140

CODEN: HMGE5; ISSN: 0964-6906

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB **Psoriasis** is an inflammatory skin disease of unknown origin, but with a clear genetic component. The strongest genetic association has been found with the major histocompatibility complex (MHC) region, and specifically between susceptibility to familial early onset **psoriasis** and human leukocyte antigen (HLA)-Cw6. The basis of this association of the HLA-C locus with disease pathogenesis is, however, not clear, and it is possible that other genes, or a combination of genes, in the HLA region are of functional importance. The MHC S gene is expressed specifically in keratinocyte differentiation and, being located 160 kb telomeric of HLA-C, is a plausible candidate gene. The authors analyzed the allelic distribution of two polymorphisms in the MHC S gene (at +619 and +1243) in a case-control association study. The authors could confirm a significant association between **psoriasis** and HLA-Cw6 [odds ratio (OR) = 7.75]. No association was found between disease (or any subtypes) and the MHC S gene polymorphism at position +619, despite its close proximity to HLA-C and the strong linkage disequilibrium between the loci. However, a

significant trend with the rarer allele at MHC S (+1243) and **psoriasis** was detected in the overall data set (OR = 2.66; P=2 x 10<sup>-9</sup>). This effect was most pronounced in the type 1a (early onset) psoriatics (OR = 3.43). Furthermore, homozygosity for the associated allele at MHC S (+1243) increased the risk of disease over that for carriage of HLA-Cw6 alone (OR = 9.38), suggesting that allele 2 of MHC S (+1243) provides an addnl. risk in **psoriasis** susceptibility. The strong association found here, coupled with the biol. involvement of the MHC S gene product corneodesmosin in skin physiol., implicates this locus (or a haplotype across HLA-C and MHC S) in the impaired desquamation characteristic of **psoriasis**.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1993:163655 CAPLUS

DOCUMENT NUMBER: 118:163655

TITLE: Retinol-binding protein receptor and complex

INVENTOR(S): **Bavik, Claes O.**; Eriksson, Erik; Allen, Rodger A.; Peterson, Per A.

PATENT ASSIGNEE(S): Scripps Research Institute, USA

SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9302694	A1	19930218	WO 1992-US6383	19920803
W: AU, BR, CA, CS, FI, HU, JP, KP, KR, PL, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
AU 9224040	A1	19930302	AU 1992-24040	19920803
PRIORITY APPLN. INFO.:			US 1991-740006	A 19910802
			WO 1992-US6383	A 19920803

AB Retinol binding protein (RBP) receptor from retinal pigment epithelium is partially purified and characterized. This glycoprotein receptor can be used for treatment of vitamin A- or retinol-associated diseases or disorders. Antibodies to the receptor are claimed, as is use of the receptor for ligand identification. The receptor reaches maximal binding with RBP within 10 min at 37°, and has a K<sub>d</sub> at 0° of 31 nM. The half-life of the receptor-RBP complex is 8.3 min at 0°.

=> d his

(FILE 'HOME' ENTERED AT 09:41:57 ON 04 FEB 2005)

FILE 'CAPLUS' ENTERED AT 09:42:03 ON 04 FEB 2005

E WARD, S?/AU

E WARD S?/AU

E WARD SIMON/AU

L1 43 S E3-E5

E BAVIK CLAES/AU

L2 18 S E3-E5

E CORK MICHAEL/AU

L3 24 S E3-E4

E TAZI-AAHNINI RACHID/AU

E TAZIAAHNINI RACHID/AU

L4 71 S L1 OR L2 OR L3

FILE 'STNGUIDE' ENTERED AT 09:46:14 ON 04 FEB 2005

FILE 'CAPLUS' ENTERED AT 09:48:23 ON 04 FEB 2005

L5 1 S L4 AND (CARBENOXOLONE? OR CARBENEOXOLONE? OR CARBENOXALONE?)  
E PSORIASIS  
L6 11209 S E3  
L7 11 S L4 AND L6

=> d 15

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2002:157589 CAPLUS  
DN 136:210549  
TI Retinol binding protein receptor-related treatment of hyperproliferative diseases  
IN Ward, Simon; Bavik, Claes; Cork, Michael;  
Tazi-Ahnini, Rachid  
PA University of Sheffield, UK  
SO PCT Int. Appl., 139 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002015920	A2	20020228	WO 2001-GB3694	20010817
	WO 2002015920	A3	20021017		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2419840	AA	20020228	CA 2001-2419840	20010817
	AU 2001078632	A5	20020304	AU 2001-78632	20010817
	EP 1318836	A2	20030618	EP 2001-956713	20010817
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004506691	T2	20040304	JP 2002-520841	20010817
	US 2003119715	A1	20030626	US 2002-85239	20020227
PRAI	GB 2000-20351	A	20000817		
	WO 2001-GB3694	W	20010817		